(Q44602862)

4 December 2017

title

Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy (English)

1 reference

4 December 2017

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

16 March 2024

author name string

Can Li

1

1 reference

4 December 2017

Chul Woo Yang

2

1 reference

4 December 2017

Joo Hyun Park

3

1 reference

4 December 2017

Sun Woo Lim

4

1 reference

4 December 2017

Bo Kyung Sun

5

1 reference

4 December 2017

Ju Young Jung

6

1 reference

4 December 2017

Soon Bae Kim

7

1 reference

4 December 2017

Yong Soo Kim

8

1 reference

4 December 2017

Jin Kim

9

1 reference

4 December 2017

Byung Kee Bang

10

1 reference

4 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14519596

16 March 2024

publication date

30 September 2003

1 reference

full work available at URL

4 December 2017

https://www.physiology.org/doi/pdf/10.1152/ajprenal.00428.2002

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

American Journal of Physiology - Renal Physiology

16 March 2024

published in

1 reference

4 December 2017

volume

286

1 reference

4 December 2017

issue

1

1 reference

4 December 2017

page(s)

F46-57

1 reference

Inflammatory bio-markers and cardiovascular risk prediction

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Chronic hydroxymethylglutaryl coenzyme a reductase inhibition and endothelial function of the normocholesterolemic rat: comparison with angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Prevention of chronic rejection by pravastatin in a rat kidney transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

The long-term course of cyclosporine-associated chronic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Rat C-reactive protein activates the autologous complement system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

C-reactive protein is associated with renal function abnormalities in a non-diabetic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Influence of the renin-angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00428.2002

Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril

16 March 2024

3

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Cyclosporine arteriolopathy: effects of drug withdrawal

16 March 2024

10

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes and is identical to osteopontin (secreted phosphoprotein I, 2aR)

16 March 2024

11

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle Cells in Culture

16 March 2024

14

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

The kidney as a second site of human C-reactive protein formation in vivo

16 March 2024

18

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Rapid reversal of endothelial dysfunction in hypercholesterolaemic rabbits treated with simvastatin and pravastatin

16 March 2024

20

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Osteopontin expression in the kidney during unilateral ureteral obstruction

16 March 2024

22

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration

16 March 2024

27

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Effects of cyclosporine in osteopontin null mice

16 March 2024

34

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation

16 March 2024

38

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Central methysergide prevents renal sympathoinhibition and bradycardia during hypotensive hemorrhage.

16 March 2024

39

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis

16 March 2024

40

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells

16 March 2024

44

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Inhibition of monocyte chemotactic protein-1 synthesis by statins

16 March 2024

45

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Sodium depletion enhances fibrosis and the expression of TGF-β1 and matrix proteins in experimental chronic cyclosporine nephropathy

16 March 2024

48

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy

16 March 2024

49

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Oral supplementation of L-arginine prevents chronic cyclosporine nephrotoxicity in rats

16 March 2024

56

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy

16 March 2024

57

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

The effects of pravastatin on hyperlipidemia in renal transplant recipients

16 March 2024

58

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity

16 March 2024

59

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II

16 March 2024

60

1 reference

https://api.crossref.org/works/10.1152/AJPRENAL.00428.2002

16 March 2024

Identifiers

1 reference

4 December 2017

1 reference